GlassScriptPhysician profile
Deokchol Parish
NPI 1841885142
$1,481.78
in general payments reported to CMS, 2019-2025
22 companies · $957 in 2025
The $957 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.65 · 2023: $269 · 2024: $229 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $215.63 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $207.68 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Antares Pharma, INC. | $172.02 | 2025 | Xyosted |
| Novo Nordisk INC | $151.36 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $144.32 | 2023-2025 | |
| Intra-Sana Laboratories | $111.84 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Amgen INC. | $108.52 | 2025 | Repatha, Otezla, Tezspire |
| Abbvie INC. | $53.17 | 2025 | |
| Corcept Therapeutics | $37.93 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $31.47 | 2025 | |
| Sumitomo Pharma America, INC. | $30.87 | 2025 | Gemtesa |
| Exact Sciences Corporation | $30.27 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $27.65 | 2022 | |
| Gilead Sciences, INC. | $24.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.48 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $22.27 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $15.32 | 2023 | Shingrix, Boostrix |
| Dexcom, INC. | $15.00 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $14.31 | 2025 | Injectafer |
| Merz North America, INC. | $14.19 | 2025 | |
| Acadia Pharmaceuticals INC | $14.09 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deokchol Parish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.